Efficacy and cost of G-CSF derivatives for prophylaxis of febrile neutropenia in lymphoma and multiple myeloma patients underwent autologous hematopoietic stem cell transplantation

References

• Ziakas PD, Kourbeti IS. Pegfilgrastim vs. filgrastim for supportive care after autologous stem cell transplantation: can we decide? Clin Transplant. 2012;26(1):16–22.
   PubMed Web of Science ®Google Scholar
• Potter A, Beck B, Ngorsuraches S. Tbo-filgrastim versus filgrastim for stem cell mobilization and engraftment in autologous hematopoietic stem cell transplant patients: A retrospective review. J Oncol Pham Pract. 2020 Jan;26(1):23–28.
   PubMed Web of Science ®Google Scholar
• Restelli U, Croce D, Bonizzoni E, et al. Monocentric analysis of the effectiveness and financial consequences of the Use of lenograstim versus filgrastim for mobilization of peripheral blood progenitor cells in patients with Lymphoma and Myeloma receiving chemotherapy and autologous stem cell transplantation. J Blood Med. 2020 Apr 2;11:123–130.
   PubMed Web of Science ®Google Scholar
• Gardellini A, Gigli F, Babic A, et al. Filgrastim XM02 (tevagrastim) after autologous stem cell transplantation compared to lenograstim: favourable cost-efficacy analysis. Ecancermedicalscience. 2013 Jun 25;7:327.
   PubMedGoogle Scholar
• Rifkin R, Spitzer G, Orloff G, et al. Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2010 Jun;10(3):186–191.
   PubMed Web of Science ®Google Scholar
• Gerds A, Fox-Geiman M, Dawravoo K, et al. Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2010 May;16(5):678–685.
   PubMed Web of Science ®Google Scholar
• Castagna L, Bramanti S, Levis A, et al. Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support. Ann Oncol. 2010 Jul;21(7):1482–1485.
   PubMed Web of Science ®Google Scholar
• Ballestrero A, Boy D, Gonella R, et al. Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas. Znn Hematol. 2008;87(1):49–55.
   Web of Science ®Google Scholar
• Samaras P, Buset EM, Siciliano RD, et al. Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation. Oncology. 2010;79(1-2):93–97.
   PubMed Web of Science ®Google Scholar
• Vidriales B, del Canizo MC, Corral M, et al. BEAM chemotherapy followed by autologous stem cell support in lymphomapatients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant. 1997 Sep;20(6):451–458.
   PubMed Web of Science ®Google Scholar
• Robinson SP, Boumendil A, Finel H, et al. High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: no differences in toxicity or outcome. A matched-control study of the EBMT-lymphoma Working party. Bone Marrow Transplant 2018 Dec;53(12):1553–1559.
   PubMed Web of Science ®Google Scholar
• Auner HW, Iacobelli S, Sbianchi G, et al. Elphalan 140 mg/m(2) or 200 mg/m(2) for autologous transplantation in myeloma: results from the collaboration to collect autologous transplant outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT chronic malignancies Working party. Haematologica. 2018;103(3):514–521.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang Y, Fan T, et al. Effective mobilization with etoposide and cyclophosphamide for collection of peripheral blood stem cell in patients with multiple myeloma. Clin Invest Med. 2020 Sep 24;43(3):E27–E32.
   PubMed Web of Science ®Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the european organization for research and treatment of cancer/invasive fungal Infections cooperative group and the National Institute of allergy and infectious diseases mycoses study group (EORTC/MSG) Consensus group. Clin Infect Dis. 2008 Jun 15;46(12):1813–1821.
   PubMed Web of Science ®Google Scholar
• Moore DC, Pellegrino AE. Pegfilgrastim-Induced Bone pain: A review on incidence, risk factors, and evidence-based management. Ann Pharmacother. 2017;51(9):797–803.
   PubMed Web of Science ®Google Scholar
• Bond TC, Szabo E, Gabriel S, et al. Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events. J OncolPharm Pract. 2018 Sep;24(6):412–423.
   Google Scholar
• Kataoka T, Sakurashita H, Taogoshi T, et al. Comparison of pegfilgrastim and filgrastim for the primary prophylactic effect for preventing febrile neutropenia in patients undergoing rituximab with dose-adjusted EPOCH chemotherapy. Yakugaku Zasshi. 2019;139(4):629–633.
   PubMed Web of Science ®Google Scholar
• Kim MG, Han N, Lee EK, et al. Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis. Bone Marrow Transplant. 2015 Apr;50(4):523–530.
   PubMed Web of Science ®Google Scholar
• Abid MB, De Mel S, Abid MA, et al. Pegylated filgrastim versus filgrastim for stem cell mobilization in multiple myeloma after novel agent induction. Clin Lymphoma Myeloma Leuk. 2018;18(3):174–179.
   PubMed Web of Science ®Google Scholar
• Wannesson L, Luthi F, Zucca E, et al. Pegfilgrastim to accelerate neutrophil engraftment following peripheral blood stem cell transplant and reduce the duration of neutropenia, hospitalization, and use of intravenous antibiotics: a phase II study in multiple myeloma and lymphoma and comparison with filgrastim-treated matched controls. Leuk Lymphoma. 2011;52(3):436–443.
   PubMed Web of Science ®Google Scholar
• Musto P, Scalzulli PR, Melillo L, et al. Peg-Filgrastim after autologous peripheral blood stem cell transplantation in hematological malignancies. Blood. 2004;104:384b.
   Web of Science ®Google Scholar
• Jagasia MH, Greer JP, Morgan DS, et al. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study. Bone Marrow Transplant 2005;35(12):1165–1169.
   PubMed Web of Science ®Google Scholar
• Vanstraelen G, Frere P, Ngirabacu MC, et al. Pegfilgrastim compared with filgrastim after autologous hematopoietic peripheral blood stem cell transplantation. Exp HematoL. 2006;34(3):382–388.
   PubMed Web of Science ®Google Scholar
• Bassi S, Rabascio C, Nassi L, et al. A single dose of pegfilgrastim versus daily filgrastim to evaluate the mobilization and the engraftment of autologous peripheral hematopoietic progenitors in malignant lymphoma patients candidate for high-dose chemotherapy. Transfus Apher Sci. 2010 Dec;43(3):321–326.
   PubMed Web of Science ®Google Scholar
• Samaras P, Blickenstorfer M, Siciliano RD, et al. Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim. Ann Hematol. 2011;90(1):89–94.
   PubMed Web of Science ®Google Scholar
• Martino M, Pratico G, Messina G, et al. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. Eur J Haematol. 2006;77(5):410–415.
   PubMed Web of Science ®Google Scholar
• Ding X, Huang W, Peng Y, et al. Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma. Ann Hematol. 2020 Jun;99(6):1331–1339.
   PubMed Web of Science ®Google Scholar
• Kahl C, Sayer HG, Hinke A, et al. Early versus late administration of pegfilgrastim after high-dose chemotherapy and autologous hematopoietic stem cell transplantation. J Cancer Res Clin Oncol. 2012 Mar;138(3):513–517.
   PubMed Web of Science ®Google Scholar
• Cesaro S, Nesi F, Tridello G, et al. A randomized, non-inferiority study comparing efficacy and safety of a single dose of pegfilgrastim versus daily filgrastim in pediatric patients after autologous peripheral blood stem cell transplant. PLoS One. 2013;8(1):e53252.
   PubMed Web of Science ®Google Scholar
• Sebban C, Lefranc A, Perrier L, et al. A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study). Eur J Cancer. 2012;48(5):713–720.
   PubMed Web of Science ®Google Scholar